Roche reported phase‑2 results for CT‑388, a dual GLP‑1/GIP receptor agonist, showing a placebo‑adjusted weight loss of about 22.5% at 48 weeks in patients with obesity. The company announced plans to move CT‑388 into Phase‑3 testing by the end of March. Roche acquired the asset through its takeover of Carmot Therapeutics and now positions CT‑388 against a crowded GLP‑1/GIP field. Company data show efficacy comparable to earlier mid‑stage results from market leaders, but Roche must prove commercial differentiation and long‑term tolerability to capture market share. Analysts noted the program is years behind incumbents; the Phase‑3 timeline and combination strategies will determine CT‑388’s competitive positioning.